SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following the FDA approval of its oral Wegovy pill for weight loss and cardiovascular risk reduction, a development the community is hailing as a significant game-changer. Investors anticipate a substantial market impact due to the convenience of a pill over injectables, with many discussing its perceived superior efficacy and the potential for a significant short squeeze as the company prepares for an early launch.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining significant attention following the news that the US Department of Commerce has selected it, along with Chainlink, to publish official GDP data on-chain, underscoring its real-world utility in decentralized finance. This development, coupled with its token buyback program funded by Pyth PRO revenue, has the community actively discussing its position as a key oracle in the crypto ecosystem.

Starfighters Space Inc

Starfighters Space Inc (FJET) is soaring and sparking intense debate following its recent IPO, with a rally attributed by some to a "new executive order" or broader "Trump space announcement" electrifying the aerospace sector. Bulls are forecasting a multi-day run and significant gains, fueled by its low float and potential for a short squeeze. However, skeptics caution it's a "pump and dump," highlighting concerns about its early-stage business, lack of an FAA launch license, and zero revenue amidst rapid price movements.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent drill program updates reporting exceptionally high-grade silver results from its Vortex zone, sparking significant bullish sentiment within the investment community. This excitement is amplified by ongoing discussions about rising precious metals prices and prominent investor Eric Sprott's continued substantial share acquisitions, with many also noting the stock's performance since AMC divested most of its stake.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is actively discussed due to the impending launch of its BlueBird 6 satellite and the rapid production cadence for subsequent BlueBird units, positioning it as a key player in the burgeoning direct-to-device space communications sector. Community sentiment is highly charged, with bulls touting the company's disruptive patented technology and long-term growth potential, while bears highlight its current valuation metrics and caution against execution risks, making its operational progress a focal point for investors.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X is gaining significant attention as its merger target, Infleqtion, makes waves with key defense contracts, including successful quantum navigation trials with the Royal Navy and strategic partnerships with entities like Oak Ridge National Laboratory. The community is actively discussing Infleqtion's advanced quantum sensing technologies as crucial for national security in GPS-denied environments, bolstered by positive endorsements from research firms comparing its potential favorably to established quantum peers. Anticipation for the upcoming merger and its potential to unlock further institutional investment is driving bullish sentiment.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as gold surges to new all-time highs, fueled by mounting expectations of central bank rate cuts and ongoing geopolitical tensions. The community is actively debating whether this reflects gold's role as a critical hedge against economic uncertainty and potential currency debasement, or if the current rally signifies an overextended 'bubble' poised for a pullback.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending following its largest-ever contract, an $816 million award from the U.S. Space Development Agency for missile-tracking satellites, alongside achieving a record 21 successful Electron launches for the year. Community sentiment is largely bullish, celebrating the company's execution and growing role as a defense contractor, though some traders anticipate profit-taking after its recent significant gains.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending as community discussion amplifies around its strategic expansion into new anticoagulation assets and the ongoing collaboration with a major healthcare leader for its lead candidate, tecarfarin. While many highlight tecarfarin's potential with key regulatory designations and a large market opportunity, others express significant concerns regarding the company's cash position and the potential for further dilutive financing. Investors are closely watching how the company balances its clinical development progress in the promising anticoagulation sector against its ongoing capital needs.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Community excitement is surging around Omeros (OMER) as it nears a crucial PDUFA decision for narsoplimab by December 26th, a potential first-in-class treatment for life-threatening TA-TMA. This binary event is amplified by the recently closed, multi-billion-dollar Novo Nordisk collaboration and a new share repurchase program, significantly de-risking the company and sparking widespread speculation about a substantial short squeeze and future valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Current Price	$1.42
Prev Close	$1.28
Open	$1.28
Dividend Yield	0.00%
50-Day Moving Average	$1.12
Beta	1.19
Avg. Volume	278,495.26
PE Ratio	-1.16

52-Week High	$4.07
52-Week Low	$0.8099
Market Capitalization	$21.34M
EPS (Annual)	-$1.20
Price to Book	1.29
Revenue Per Employee	$1.32M
Enterprise Value/EBITDA	N/A

MRKR
Marker Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MRKR News

MRKRMarker Therapeutics Inc